Patents by Inventor Toshio Sada

Toshio Sada has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20190149802
    Abstract: A robot includes a shoulder, an arm connected to the shoulder, an imaging device that is connected to the shoulder via a support, and an image receiver that receives a captured image captured by the imaging device, and a robot controller that controls the arm based on the captured image, and in which the imaging device is two sets of stereo cameras having different depths of field.
    Type: Application
    Filed: November 15, 2018
    Publication date: May 16, 2019
    Inventors: Toshio TANAKA, Shunsuke SADA
  • Patent number: 7795281
    Abstract: The optically active compound (R)-2-amino-1,4-dihydro-6-methyl-4-(3 -nitrophenyl)-3,5-pyridinedicarboxylic acid 3-(1-diphenylmethylazetidin-3-yl) ester 5 -isopropyl ester or a pharmacologically acceptable salt thereof, and a method using the compound or its salt to treat circulatory diseases.
    Type: Grant
    Filed: June 24, 2008
    Date of Patent: September 14, 2010
    Assignees: Daiichi Sankyo Company, Limited, Ube Industries, Ltd.
    Inventors: Takashi Kobayashi, Toshio Sada
  • Publication number: 20080287411
    Abstract: The optically active compound (R)-2-amino-1,4-dihydro-6-methyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylic acid 3-(1-diphenylmethylazetidin-3-yl) ester 5-isopropyl ester or a pharmacologically acceptable salt thereof, and a method using the compound or its salt to treat circulatory diseases.
    Type: Application
    Filed: June 24, 2008
    Publication date: November 20, 2008
    Applicants: SANKYO COMPANY, LIMITED, UBE INDUSTRIES, LTD.
    Inventors: Takashi Kobayashi, Toshio Sada
  • Publication number: 20080214626
    Abstract: A method for the prevention and/or treatment of a disease caused by hypertension comprising administering to a mammal, such as a human, in need thereof pharmaceutically effective amounts of (5-methyl-2-oxo-1,3-dioxolen-4-yl)methyl 4-(1-hydroxy-1-methylethyl)-2-propyl-1-[[2?-(1H-tetrazol-5-yl(biphenyl-4-yl]methyl]imidazol-5-carboxylate and a calcium channel blocker which is amlodipine or amlodipine besylate.
    Type: Application
    Filed: March 6, 2008
    Publication date: September 4, 2008
    Applicant: DAIICHI SANKYO COMPANY, LIMITED
    Inventors: Masatsugu Horiuchi, Masaru Iwai, Toshio Sada, Makoto Mizuno
  • Publication number: 20080176910
    Abstract: Methods for the prevention and/or treatment of arteriosclerosis and restenosis following percutaneous coronary intervention or sudden death and for the inhibition of vascular smooth muscle cells, neointima formulation of blood vessels or vascular remodeling comprising administering to a mammal, such as a human, in need thereof pharmaceutically effective amounts of an angiotensin II receptor antagonist which is (5-methyl-2-oxo-1,3-dioxolen-4-yl)methyl 4-(1-hydroxy-1-methylethyl)-2-propyl-1-[[2?-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]imidazol-5-carboxylate and a calcium channel blocker which is amlodipine or amlodipine besylate.
    Type: Application
    Filed: March 6, 2008
    Publication date: July 24, 2008
    Applicant: DAIICHI SANKYO COMPANY, LIMITED
    Inventors: Masatsugu Horiuchi, Masaru Iwai, Toshio Sada, Makoto Mizuno
  • Publication number: 20080176909
    Abstract: Methods for the prophylaxis and/or treatment of arteriosclerosis, hypertension, restenosis, heart diseases, renal diseases and cerebrovascular diseases by administering a pharmaceutical composition comprising the following active ingredients: (A) an angiotensin II receptor antagonist selected from the group consisting of a compound having a formula (I), a pharmacologically acceptable ester thereof and a pharmacologically acceptable salt thereof (for example, olmesartan medoxomil), the compound having the following formula: and (B) a calcium channel blocker selected from the group consisting of a 1,4-dihydropyridine compound and a pharmacologically acceptable salt thereof (for example, azelnidipine), wherein the composition does not include the combination of olmesartan medoxomil and amlodipine or amlodipine besylate.
    Type: Application
    Filed: March 6, 2008
    Publication date: July 24, 2008
    Applicant: DAIICHI SANKYO COMPANY, LIMITED
    Inventors: Masatsugu Horiuchi, Masaru Iwai, Toshio Sada, Makoto Mizuno
  • Publication number: 20060252806
    Abstract: A pharmaceutical composition comprising the following active ingredients: (A) an angiotensin II receptor antagonist selected from the group consisting of a compound having a formula (I), a pharmacologically acceptable ester thereof and a pharmacologically acceptable salt thereof (for example, olmesartan medoxomil); and (B) a calcium channel blocker selected from the group consisting of a 1,4-dihydropyridine compound and a pharmacologically acceptable salt thereof (for example, azelnidipine), wherein the composition does not include the combination of olmesartan medoxomil and amlodipine. The composition is useful for prophylaxis and/or treatment of arteriosclerosis, hypertension, heart diseases, renal diseases and cerebrovascular diseases.
    Type: Application
    Filed: July 11, 2006
    Publication date: November 9, 2006
    Applicant: SANKYO COMPANY LIMITED
    Inventors: Masatsugu Horiuchi, Masaru Iwai, Toshio Sada, Makoto Mizuno
  • Publication number: 20060252805
    Abstract: A pharmaceutical composition comprising the following active ingredients: (A) an angiotensin II receptor antagonist which is (5-methyl-2-oxo-1,3-dioxolen-4-yl)methyl 4-(1-hydroxy-1-methylethyl)-2-propyl-1 [[2?-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]imidazol-5-carboxylate and (B) a calcium channel blocker which is amlodipine. The composition is useful for the prophylaxis and/or treatment of arteriosclerosis, hypertension, heart diseases, renal diseases or cerebrovascular diseases.
    Type: Application
    Filed: July 11, 2006
    Publication date: November 9, 2006
    Applicant: SANKYO COMPANY LIMITED
    Inventors: Masatsugu Horiuchi, Masaru Iwai, Toshio Sada, Makoto Mizuno
  • Publication number: 20060009502
    Abstract: A pharmaceutical composition comprising the following active ingredients: (A) an angiotensin II receptor antagonist selected from the group of a compound having a formula (I), a pharmacologically acceptable ester thereof and a pharmacologically acceptable salt thereof (for example, olmesartan medoxomil); and (B) a calcium channel blocker selected from the group consisting of a 1,4-dihydropyridine compound and a pharmacologically acceptable salt thereof (for example, azelnidipine), for the prophylaxis and/or treatment of arteriosclerosis, hypertension, heart diseases, renal diseases or cerebrovascular diseases.
    Type: Application
    Filed: July 22, 2005
    Publication date: January 12, 2006
    Applicant: SANKYO COMPANY, LIMITED
    Inventors: Masatsugu Horiuchi, Masaru Iwai, Toshio Sada, Makoto Mizuno
  • Publication number: 20050272715
    Abstract: The optically active compound (R)-2-amino-1,4-dihydro-6-methyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylic acid 3-(1-diphenylmethylazetidin-3-yl) ester 5-isopropyl ester or a pharmacologically acceptable salt thereof, and a method using the compound or its salt to treat circulatory diseases.
    Type: Application
    Filed: June 17, 2005
    Publication date: December 8, 2005
    Applicants: SANKYO COMPANY, LIMITED, UBE INDUSTRIES, LTD.
    Inventors: Takashi Kobayashi, Toshio Sada
  • Publication number: 20050113367
    Abstract: A pharmaceutical composition which comprises (i) an angiotensin II receptor antagonist having the following formula (I), a pharmacologically acceptable salt thereof, a pharmacologically acceptable ester thereof or a pharmacologically acceptable salt of such ester, and (ii) a diuretic which is at least one thiazide compound: The pharmaceutical composition has an excellent hypotensive effect and low toxicity, and therefore is useful as a medicament for treating hypertension or heart disease.
    Type: Application
    Filed: December 23, 2004
    Publication date: May 26, 2005
    Applicant: SANKYO COMPANY, LIMITED
    Inventors: Toshio Sada, Makoto Mizuno
  • Patent number: 6878703
    Abstract: A pharmaceutical composition comprises an angiotensin II receptor antagonist selected from among compounds having the following formula (I), a pharmacologically acceptable salt thereof, a pharmacologically acceptable ester thereof and a pharmacologically acceptable salt of such ester, and one or more diuretics: The pharmaceutical composition of the present invention has an excellent hypotensive effect and low toxicity, and therefore is useful as a medicament for preventing or treating hypertension or heart disease.
    Type: Grant
    Filed: May 20, 2003
    Date of Patent: April 12, 2005
    Assignee: Sankyo Company, Limited
    Inventors: Toshio Sada, Makoto Mizuno
  • Publication number: 20040198788
    Abstract: A pharmaceutical composition for administering an angiotensin II receptor antagonist and an ACAT inhibitor. A method for preventing or treating arteriosclerosis or ischemic heart disease.
    Type: Application
    Filed: February 26, 2004
    Publication date: October 7, 2004
    Applicant: SANKYO COMPANY, LIMITED
    Inventors: Toshio Sada, Toshimori Inaba
  • Publication number: 20040002529
    Abstract: A pharmaceutical composition comprises an angiotensin II receptor antagonist selected from among compounds having the following formula (I), a pharmacologically acceptable salt thereof, a pharmacologically acceptable ester thereof and a pharmacologically acceptable salt of such ester, and one or more diuretics: 1
    Type: Application
    Filed: May 20, 2003
    Publication date: January 1, 2004
    Applicant: SANKYO COMPANY, LIMITED
    Inventors: Toshio Sada, Makoto Mizuno
  • Patent number: 6610682
    Abstract: A pharmaceutical composition comprising as its active ingredients one or more drugs selected from the group consisting of angiotensin II receptor antagonists and angiotensin converting enzyme inhibitors, and one or more insulin resistance improving agents exhibits excellent arteriosclerotic progress inhibitory effects, and is useful as a drug, particularly as a drug for the prevention or treatment of arteriosclerosis. The invention also provides a method for the treatment or prophylaxis of arteriosclerosis by administering in combination (i) at least one of said angiotensin II receptor antagonists or angiotensin converting enzyme inhibitors and (ii) one or more insulin resistance improving agents to a mammal suffering from or susceptible to arteriosclerosis.
    Type: Grant
    Filed: August 21, 2001
    Date of Patent: August 26, 2003
    Assignee: Sankyo Company, Limited
    Inventors: Yoshio Tsujita, Toshihiko Fujiwara, Toshio Sada, Naoyuki Maeda
  • Publication number: 20020013308
    Abstract: A pharmaceutical composition comprising as its active ingredients one or more drugs selected from the group consisting of angiotensin II receptor antagonists and angiotensin converting enzyme inhibitors, and one or more insulin resistance improving agents exhibits excellent arteriosclerotic progress inhibitory effects, and is useful as a drug, particularly as a drug for the prevention or treatment of arteriosclerosis. The invention also provides a method for the treatment or prophylaxis of arteriosclerosis by administering in combination (i) at least one of said angiotensin II receptor antagonists or angiotensin converting enzyme inhibitors and (ii) one or more insulin resistance improving agents to a mammal suffering from or susceptible to arteriosclerosis.
    Type: Application
    Filed: August 21, 2001
    Publication date: January 31, 2002
    Applicant: SANKYO COMPANY LIMITED
    Inventors: Yoshio Tsujita, Toshihiko Fujiwara, Toshio Sada, Naoyuki Maeda
  • Patent number: 5646171
    Abstract: An angiotensin II antagonist of the formula: ##STR1## in which: R.sub.p.sup.1 represents hydrogen, C.sub.1 -C.sub.6 alkyl, C.sub.3 -C.sub.6 cycloalkyl or C.sub.1 -C.sub.6 alkanoyl; R.sub.p.sup.2 represents a single bond, C.sub.1 -C.sub.4 alkylene or C.sub.1 -C.sub.4 alkylidene; R.sub.p.sup.3 and R.sub.p.sup.4 are independently selected from the group consisting of hydrogen and C.sub.1 -C.sub.6 alkyl; R.sub.p.sup.5 represents hydrogen, C.sub.1 -C.sub.4 alkyl, phenyl, naphthyl, benzyl, diphenylmethyl, naphthylmethyl, alkanoyloxyalkyl, cycloalkanecarbonyloxyalkyl, alkoxycarbonyloxyalkyl, cycloalkyloxycarbonyloxyalkyl, (5-phenyl-2-oxo-1,3-dioxolen-4-yl)methyl, (5-alkyl-2-oxo-1,3-dioxolen-4-yl)methyl or phthalaidyl; R.sub.p.sup.6 represents a carboxy or a tetrazol-5-yl; and X.sub.p represents an oxygen or sulfur, and pharmaceutically acceptable salts thereof. The compounds have hypotensive activity and can thus be used for the treatment and prophylaxis of hypertension.
    Type: Grant
    Filed: June 5, 1995
    Date of Patent: July 8, 1997
    Assignee: Sankyo Company, Limited
    Inventors: Hiroaki Yanagisawa, Yoshiya Amemiya, Yasuo Shimoji, Takuro Kanazaki, Hiroyuki Koike, Toshio Sada
  • Patent number: 5616599
    Abstract: Compounds of the following formula (I) or the formula (I).sub.p : ##STR1## wherein R.sup.1 is alkyl or alkenyl; R.sup.2 and R.sup.3 are hydrogen, alkyl, alkenyl, cycloalkyl, aralkyl, aryl, or aryl fused to cycloalkyl; R.sup.4 is hydrogen, alkyl, alkanoyl, alkenoyl, arylcarbonyl, alkoxycarbonyl, tetrahydropyranyl, tetrahydrothiopyranyl, tetrahydrothienyl, tetrahydrofuryl, a group of formula --SiR.sup.a R.sup.b R.sup.c, in which R.sup.a, R.sup.b and R.sup.c are alkyl or aryl, alkoxymethyl, (alkoxyalkoxy)methyl, haloalkoxymethyl, aralkyl, aryl or alkanoyloxymethoxycarbonyl; R.sup.5 is carboxy or --CONR.sup.8 R.sup.9, wherein R.sup.8 and R.sup.9 hydrogens or alkyl, or R.sup.8 and R.sup.9 together form alkylene; R.sup.6 is hydrogen, alkyl, alkoxy or halogen; R.sup.7 is carboxy or tetrazol-5-yl; R.sub.p.sup.1 is hydrogen, alkyl, cycloalkyl or alkanoyl; R.sub.p.sup.2 is a single bond, alkylene or alkylidene; R.sub.p.sup.3 and R.sub.p.sup.4 are each hydrogen or alkyl; R.sub.p.sup.6 is carboxy or tetrazol-5-yl; and X.
    Type: Grant
    Filed: January 26, 1995
    Date of Patent: April 1, 1997
    Assignee: Sankyo Company, Limited
    Inventors: Hiroaki Yanagisawa, Koichi Fujimoto, Yoshiya Amemiya, Yasuo Shimoji, Takuro Kanazaki, Hiroyuki Koike, Toshio Sada
  • Patent number: 5459148
    Abstract: Compounds of formula (I): ##STR1## [wherein: A represents a group (IIa), (IIb) or (IIc): ##STR2## R.sup.1 is alkyl, alkenyl, cycloalkyl or a group of formula R.sup.4 --Y--R.sup.5 --, where: R.sup.4 is hydrogen, alkyl, or cycloalkyl, R.sup.5 is a single bond or alkylene, and Y is oxygen, sulfur or imino group; R.sup.2 is hydrogen, halogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted cycloalkyl, hydroxy, amino, alkylamino, dialkylamino, formyl, alkylcarbonyl, alkoxy, alkylthio, cyano or nitro; R.sup.3 is hydrogen, alkyl, carboxy, protected carboxy, carbamoyl or tetrazol-5-yl; X is of formula --CH.dbd., --N.dbd. or --C(COOR.sup.6).dbd., where R.sup.
    Type: Grant
    Filed: October 27, 1994
    Date of Patent: October 17, 1995
    Assignee: Sankyo Company, Limited
    Inventors: Hiroaki Yanagisawa, Yoshiya Amemiya, Takuro Kanazaki, Yasuo Shimoji, Hiroyuki Koike, Toshio Sada
  • Patent number: 5254578
    Abstract: Compounds of the formula: ##STR1## in which: R.sup.1 is a trifluoromethyl or a pentafluoroethyl;R.sup.2 is ##STR2## in which R.sup.4 is hydrogen; .alpha.-.beta. is a carbon-carbon single bond;and pharmaceutically acceptable salts thereof, have antihypertensive activity and can thus be used for the treatment and prophylaxis of cardiovascular diseases.
    Type: Grant
    Filed: November 9, 1992
    Date of Patent: October 19, 1993
    Assignee: Sankyo Company, Limited
    Inventors: Toshihiko Hashimoto, Hidekazu Masuko, Hiroyuki Koike, Toshio Sada